Galapagos reported EUR30.67M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
argenx SE USD 321.35M 45.11M Jun/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
Biogen USD 583.8M 11.3M Jun/2025
Genmab DKK 144M 18M Jun/2025
Gilead Sciences USD 1.36B 100M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
GRIFOLS EUR 282.76M 41.9M Jun/2025
Hikma Pharmaceutical USD 288M 8M Dec/2024
Incyte USD 331.02M 5.33M Jun/2025
Merck EUR 1.48B 9M Jun/2025
Neurocrine Biosciences USD 286.3M 9.8M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Roche Holding CHF 3.61B 381M Dec/2024
Sanofi EUR 2.63B 408M Jun/2025
UCB EUR 1.29B 221M Dec/2024
Vertex Pharmaceuticals USD 424.6M 28.2M Jun/2025